The practice of selecting a drug that has been approved for one thing and prescribing it for some other purpose is known as off-label prescription. It is potentially dangerous. CTV's Relenza item, like Glaxo's press materials, promoted an off-label application of a new drug. On Nov. 4, Health Canada announced the approval of Relenza for sale by prescription. The story on Toronto's top-rated local newscast, CFTO, relied on interviews and footage supplied by the public relations firm Hill and Knowlton.
Media appears here every other week.
Printer-friendly version Top.